Open Access Open Access  Restricted Access Subscription Access
GLP-1 agonist diabetic care

Treatment of Type 2 Diabetes mellitus (T2DM): Can GLP-1 Receptor Agonists fill in the gaps?

Smriti Sharma, Vinayak Bhatia


GLP-1 receptor (GLP-1R), one of the class-B G-protein-coupled receptors (GPCR), is a budding molecular target to design drugs for treating type 2 diabetes. In this review, authors have summarized the physiological actions of Glucagon-like peptide-1 receptor (GLP-1R) and currently available drugs based on GLP-1 Receptor Agonists (GLP-1 RAs). The exemplary studies in this area have been examined in detail. GLP-1 RAs offer a chance of holistic management of this disease because they help in controlling the main condition and manage the related side effects too. Careful adjustment and monitoring of the dosage of GLP-1 receptor agonists is required to manage adverse effects.


GLP-1; Type 2 diabetes mellitus (T2DM); GLP-1 receptor agonists; Diabetes; Incretin hormone;

Full Text:


ISSN 2347–9825

Authors/visitors are advised to use Firefox browser for better experience of journal site.

Open Access: Researcher from developing/low economy countries can access the jorunal contents through WHO-HINARI .